Form 13-F position report

BIO-TECHNE CORP COM

Reported by AMERIPRISE FINANCIAL INC

TECH CUSIP 09073M104 Manager CIK 0000820027

Reported 2,815,161 shares, down 621,805 (18.1%) from the prior quarter.

Reported value -11.4%; share count -18.1% vs. the prior quarter.

Reduced
% of reported 13F value 0.04% This manager · Q3 2025
Shares 2,815,161 Quarter-end amount reported
Reported value $156,607,476 Fair value at quarter end
Consecutive quarters held 44 Through Q3 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 234988000
2021-12-31 266927000
2022-03-31 271151000
2022-06-30 215231000
2022-09-30 175648000
2022-12-31 205238000
2023-03-31 225761621
2023-06-30 259177350
2023-09-30 147028122
2023-12-31 155995793
2024-03-31 230954449
2024-06-30 293938243
2024-09-30 350540492
2024-12-31 338755554
2025-03-31 210321346
2025-06-30 176831943
2025-09-30 156607476
2025-12-31 164576211
2026-03-31 89426217
2026-06-30 3854576

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for BIO-TECHNE CORP COM held by AMERIPRISE FINANCIAL INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 54,559 -1,656,620 (-96.8%) < 0.01% $3,854,576 2026-08-14
Q1 2026 Reduced 1,711,179 -1,087,258 (-38.9%) 0.02% $89,426,217 2026-05-15
Q4 2025 Reduced 2,798,437 -16,724 (-0.6%) 0.04% $164,576,211 2026-02-17
Q3 2025 Reduced 2,815,161 -621,805 (-18.1%) 0.04% $156,607,476 2025-11-14
Q2 2025 Reduced 3,436,966 -150,400 (-4.2%) 0.04% $176,831,943 2025-08-14
Q1 2025 Reduced 3,587,366 -1,115,576 (-23.7%) 0.06% $210,321,346 2025-05-14
Q4 2024 Added 4,702,942 +317,349 (7.2%) 0.09% $338,755,554 2025-02-14
Q3 2024 Added 4,385,593 +283,175 (6.9%) 0.09% $350,540,492 2024-11-14
Q2 2024 Added 4,102,418 +821,349 (25.0%) 0.08% $293,938,243 2024-08-14
Q1 2024 Added 3,281,069 +1,259,351 (62.3%) 0.06% $230,954,449 2024-05-15
Q4 2023 Reduced 2,021,718 -138,237 (-6.4%) 0.05% $155,995,793 2024-02-14
Q3 2023 Reduced 2,159,955 -1,015,071 (-32.0%) 0.05% $147,028,122 2023-11-14
Q2 2023 Added 3,175,026 +132,006 (4.3%) 0.08% $259,177,350 2023-08-14
Q1 2023 Added 3,043,020 +566,681 (22.9%) 0.07% $225,761,621 2023-05-15
Q4 2022 Added 2,476,339* +2,639 (0.1%) 0.07% $205,238,000 2023-02-14
Q3 2022 Reduced 618,425 -2,479 (-0.4%) 0.06% $175,648,000 2022-11-14
Q2 2022 Reduced 620,904 -5,302 (-0.8%) 0.08% $215,231,000 2022-08-15
Q1 2022 Added 626,206 +110,149 (21.3%) 0.08% $271,151,000 2022-05-16
Q4 2021 Added 516,057 +31,132 (6.4%) 0.07% $266,927,000 2022-02-14
Q3 2021 Reduced 484,925 -182,029 (-27.3%) 0.08% $234,988,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

648 managers reported BIO-TECHNE CORP COM for Q3 2025.

Managers reporting BIO-TECHNE CORP COM in Q3 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Reduced 17,932,373 -505,949 0.01% $997,577,910 44 qtrs
BlackRock Inc Reduced 11,887,082 -284,134 0.01% $661,278,402 5 qtrs
MORGAN STANLEY Added 7,237,878 +658,935 0.02% $402,643,305 44 qtrs
STATE STREET CORPORATION Reduced 5,753,393 -105,190 0.01% $320,061,253 45 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 5,115,133 +3,978,026 0.05% $284,554,850 44 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 4,927,178 +864,669 0.02% $273,678,698 44 qtrs
Invesco Ltd Added 3,946,028 +283,303 0.03% $219,517,538 44 qtrs
PRICE T ROWE ASSOCIATES INC MD Reduced 3,350,144 -5,497,787 0.02% $186,370,000 44 qtrs
Neuberger Berman Group LLC Added 3,307,116 +807,147 0.13% $183,974,851 44 qtrs
MAVERICK CAPITAL LTD New 3,012,654 +3,012,654 2.24% $167,593,942 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2025
Filed
November 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
2,502,135
None
313,026

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.